🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thank you Nasdaq Exchange for hosting us for an amazing morning ringing today’s opening bell! Watch the ceremony here: bit.ly/4dufaXu $NGNE #NasdaqListed

🥼 Neurogene Inc is on a mission to improve the lives of patients and families devastated by rare neurological diseases. 🧬 The medicine Neurogene Inc. is creating has the potential to change the way these disorders are treated. 🔔 Proud to be your partner $NGNE! #NasdaqListed

We are excited to announce that the U.S. FDA has granted Regenerative Medicine Advanced Therapy #RMAT designation to NGN-401 for #RettSyndrome. Learn more: bit.ly/3T2HyZ9

Today, we reported second quarter 2024 financial results and highlighted recent updates. For full details and results, read today’s press release: bit.ly/3YELJ0O

Tune in today at 11:00 a.m. ET to watch our Founder and Chief Executive Officer, Dr. Rachel McMinn, in a fireside chat at the H.C. Wainwright & Co. 26th Annual Global Investment Conference. A link to the webcast is available here: bit.ly/4dWYFDE #HCWainwrightGlobal

Tune in today at 2:30 p.m. ET to watch our Founder and Chief Executive Officer, Dr. Rachel McMinn, in a fireside chat at the Cantor Global Healthcare Conference. A link to the webcast is available here: bit.ly/4g3hTsT #CantorHCC

Attending Cell & Gene’s 2024 Meeting on the Mesa? Don’t miss our Founder and Chief Executive Officer, Dr. Rachel McMinn, participate in a Science Slam focused on neurological disease. #CGMesa24 Alliance for Regenerative Medicine (ARM)

Interim clinical data from our Phase 1/2 trial of NGN-401 for Rett syndrome will be featured during a late-breaker at the 2024 Child Neurology Society Annual Meeting. Join our live webcast Nov 11 at 4:30 p.m. ET for a review of the data! Learn more, visit: bit.ly/3YtRgXk #CNSAM

Today we announced positive interim efficacy data from the low-dose cohort on our ongoing Phase 1/2 trial of NGN-401 gene therapy in female pediatric patients with Rett syndrome. Join our webcast today at 4:30 p.m. ET for a review of the data. Learn more: bit.ly/40OulaG

Today, we reported third quarter 2024 financial results and highlighted recent updates. For full details and results, read today’s press release: bit.ly/4eEvFjI

Tune in today at 12:40 p.m. ET to watch our Founder and Chief Executive Officer, Rachel McMinn, in a fireside chat at the Stifel 2024 Healthcare Conference. A link to the webcast is available here: bit.ly/3YYq2ae

Today, we announced that Neurogene management will present at three conferences in March, including the TD Cowen Annual Health Care Conference, Leerink Global Healthcare Conference, and Stifel Virtual CNS Forum. Learn more here: bit.ly/4gSEdol

Tune in today at 9:50 a.m. ET to watch our Founder and Chief Executive Officer, Rachel McMinn, in a fireside chat at the TD Cowen 45th Annual Health Care Conference. A link to the live webcast is available here: bit.ly/3ESHlDm

Tune in today at 1:00 p.m. ET to watch our Founder and Chief Executive Officer, Rachel McMinn, in a fireside chat at the Leerink Global Healthcare Conference. A link to the live webcast is available here: bit.ly/4he5UIn

Tune in tomorrow at 9:30 a.m. ET to watch our Founder and Chief Executive Officer, Rachel McMinn, in a fireside chat at the Stifel Virtual CNS Forum. A link to the live webcast is available here: bit.ly/4bNvvGV

Today, we reported fourth quarter and full year 2024 financial results and highlighted recent updates. For full details and results, read today’s press release: bit.ly/4lblo3g

Today we announced the publication of data in a Science Magazine journal demonstrating that NGN-401 gene therapy with our EXACT™ technology regulates transgene expression in preclinical models of #rettsyndrome. Read more: bit.ly/4i1XCDU

We had a great time participating in the BioHouston 20th Annual Chili Cook-off! We are happy to be part of a community that joins together to celebrate our shared goal of making a difference for patients and their families. #Biotech #Networking #BioHouston

Today, we reported first quarter 2025 financial results and highlighted recent updates. For full details and results, read today’s press release: bit.ly/4m8osO1

Tune in at 9:30 a.m. ET to watch our Founder and Chief Executive Officer, Rachel McMinn, in a fireside chat at the HCW 3rd Annual BioConnect Investor Conference at NASDAQ. A link to the live webcast is available here: bit.ly/4kr20Oi